Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (311-320 of 448) with videos related to

Pageof 45
Sort By:
The Journal of Rheumatology|May 9, 2008
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label studyAlice Bérezné, Brigitte Ranque, Dominique Valeyre, et al.
Rheumatology (Oxford, England)|October 12, 2022
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by regionAlain Lescoat, Dörte Huscher, Nils Schoof, et al.
Arthritis and Rheumatism|October 23, 2010
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosisMirko Manetti, Yannick Allanore, Lucile Revillod, et al.
Annals of the Rheumatic Diseases|October 29, 2010
The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotypeKaren Dawidowicz, Yannick Allanore, Mickaël Guedj, et al.
Annals of the Rheumatic Diseases|February 22, 2018
Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional studyMwidimi Ndosi, Begonya Alcacer-Pitarch, Yannick Allanore, et al.
Clinical and Experimental Rheumatology|January 9, 2016
Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohortThibault Vandhuick, Yannick Allanore, Didier Borderie, et al.
Plos One|May 23, 2012
Comparing HLA shared epitopes in French Caucasian patients with sclerodermaDoua F Azzouz, Justyna M Rak, Isabelle Fajardy, et al.
Annals of the Rheumatic Diseases|August 2, 2015
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR databaseElina G Wirz, Veronika K Jaeger, Yannick Allanore, et al.
The Lancet. Rheumatology|November 8, 2023
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux diseaseMichael Hughes, Yannick Allanore, Murray Baron, et al.
Clinical and Experimental Rheumatology|October 18, 2016
Effects of rituximab in connective tissue disorders related interstitial lung diseaseGemma Lepri, Jerome Avouac, Paolo Airò, et al.
Pageof 45

Showing results (311-320 of 448) with videos related to

Sort By:
Pageof 45
The Journal of Rheumatology|May 9, 2008
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label studyAlice Bérezné, Brigitte Ranque, Dominique Valeyre, et al.
Rheumatology (Oxford, England)|October 12, 2022
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by regionAlain Lescoat, Dörte Huscher, Nils Schoof, et al.
Arthritis and Rheumatism|October 23, 2010
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosisMirko Manetti, Yannick Allanore, Lucile Revillod, et al.
Annals of the Rheumatic Diseases|October 29, 2010
The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotypeKaren Dawidowicz, Yannick Allanore, Mickaël Guedj, et al.
Annals of the Rheumatic Diseases|February 22, 2018
Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional studyMwidimi Ndosi, Begonya Alcacer-Pitarch, Yannick Allanore, et al.
Clinical and Experimental Rheumatology|January 9, 2016
Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohortThibault Vandhuick, Yannick Allanore, Didier Borderie, et al.
Plos One|May 23, 2012
Comparing HLA shared epitopes in French Caucasian patients with sclerodermaDoua F Azzouz, Justyna M Rak, Isabelle Fajardy, et al.
Annals of the Rheumatic Diseases|August 2, 2015
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR databaseElina G Wirz, Veronika K Jaeger, Yannick Allanore, et al.
The Lancet. Rheumatology|November 8, 2023
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux diseaseMichael Hughes, Yannick Allanore, Murray Baron, et al.
Clinical and Experimental Rheumatology|October 18, 2016
Effects of rituximab in connective tissue disorders related interstitial lung diseaseGemma Lepri, Jerome Avouac, Paolo Airò, et al.
Pageof 45